Report from the NEI/FDA ophthalmic clinical trial design and endpoints symposium

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 2, 2008, Pages 479-489

  Csaky, Karl G ^a   Richman, Elaine A ^b   Ferris III, Frederick L ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Richman Associates LLC   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DORZOLAMIDE; PEGAPTANIB; RANIBIZUMAB; TIMOLOL;

CLINICAL RESEARCH; CLINICAL TRIAL; COLOR VISION; CONFERENCE PAPER; CONTRAST SENSITIVITY; DIABETIC RETINOPATHY; DRUG MECHANISM; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRAOCULAR PRESSURE; MEDICAL EDUCATION; MEDICAL INFORMATION; MEDICAL TECHNOLOGY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; VISUAL ACUITY; VISUAL FIELD; ATROPHY; BIOASSAY; HEALTH CARE ORGANIZATION; METHODOLOGY; OPHTHALMOLOGY; PATHOLOGY; PATIENT SATISFACTION; PHYSIOLOGY; PIGMENT EPITHELIUM; POSTMARKETING SURVEILLANCE; RETINA MACULA DEGENERATION; STANDARD; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UNITED STATES;

ATROPHY; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS AS TOPIC; DIABETIC RETINOPATHY; ENDPOINT DETERMINATION; HUMANS; MACULAR DEGENERATION; NATIONAL INSTITUTES OF HEALTH (U.S.); OPHTHALMOLOGY; PATIENT SATISFACTION; PIGMENT EPITHELIUM OF EYE; PRODUCT SURVEILLANCE, POSTMARKETING; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VISUAL ACUITY;

EID: 40649108602     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1132     Document Type: Conference Paper

References (18)

1. Aylward EH. Changes in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull. 2007;72:152-158.
2. The Food and Drug Modernization Act of 1977, Title 21 Code of Federal Regulations Part 31 Subpart H Section 314.500.
3. http://www.cancer.gov/Templates/db-alpha.aspx?print= 1&cdrid=44163.
4. Ferris FL 3rd, Podgor MJ, Davis MD. Macular edema in Diabetic Retinopathy Study Patients. Diabetic Retinopathy Study Report Number 12. Ophthalmology. 1987;94:754-760.
5. The Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. Ophthalmology. 2006;113:1974-1986.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
7. Cunningham ET Jr, Adamis AP, Altaweel M, et al.; Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757.
8. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533-1538.]
9. Entezari M, Ahmadieh H, Dehghan MH, Ramezani A, Bassirnia N, Anissian A. Posterior sub-tenon triamcinolone for refractory diabetic macular edema: a randomized clinical trial. Eur J Ophthalmol. 2005;15:746-750.
10. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142:961-969.
11. Klein R, Meuer SM, Moss SE, Klein BE. Retinal microaneurysm counts and 10-year progression of diabetic retinopathy. Arch Ophthalmol 1995;113:1386-1391.
12. Bengtsson B, Heijl A, Agardh E. Visual fields correlate better than visual acuity to severity of diabetic retinopathy. Diabetologia. 2005;48:2494-2500.
13. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol. 1999;117:1329-1345.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
15. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
16. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl JMed. 2006;355:1419-1431.
17. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
18. The AREDS Study Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417-1436.